Evonik introduces new product line HYPROX® AS approved under Biocidal Products Regulation 528/2012

ESSEN, 05-Jul-2017 — /EuropaWire/ — Hydrogen peroxide is used as active substance in the formulation of biocidal products and for the production of the active substance peracetic acid. Biocidal products containing hydrogen peroxide are applied in a variety of applications, e.g. as a disinfectant in water treatment, in the food and beverage industry, animal hygiene and also in the area of healthcare. Hydrogen peroxide has outstanding disinfectant properties and, as a potent antimicrobial agent, is effective against bacteria, molds and viruses, even at low concentration.

In the European Union biocidal products are subject to the Biocidal Products Regulation (BPR) (EU) Nr. 528/2012, which regulates the making available on the market and use of biocidal products in the European Union and shall harmonise the European rules for biocidal products and their active substances. The aim is to provide a high level of protection for people, animals and the environment and to ensure that products are sufficiently effective against the target organisms. The BPR stipulates a two-step process, in which the active substance evaluation is followed by a product authorisation of individual biocidal products.

With effect from February 1st, 2017, all biocidal products containing the active substance hydrogen peroxide, that are placed on the market and being supported as biocidal products under the BPR, have to be formulated with a technically equivalent active substance.

Furthermore, as of October 1st, 2017, any peracetic acid based active substances have to be produced with a technically equivalent source of hydrogen peroxide as defined in the active substance dossier for hydrogen peroxide.

To meet the demands of this regulatory requirement, Evonik has introduced the new product line HYPROX® AS besides the existing product line PERSYNT® LC. The active substances HYPROX® AS and PERSYNT® LC are both approved reference sources as defined under the Biocidal Products Regulation 528/2012.

This portfolio enhancement supports Evonik’s strategic focus as a provider of sustainable and environmentally benign solutions. Evonik is dedicated to provide the best products and services to its customers in order to support them in fulfilling the BPR requirements.

For further information please visit h2o2.evonik.com and peracetic-acid.evonik.com

Company information

Evonik is one of the world leaders in specialty chemicals. The focus on more specialty businesses, customer-orientated innovative prowess and a trustful and performance-oriented corporate culture form the heart of Evonik’s corporate strategy. They are the lever for profitable growth and a sustained increase in the value of the company. Evonik benefits specifically from its customer proximity and leading market positions. Evonik is active in over 100 countries around the world with more than 35,000 employees. In fiscal 2016, the enterprise generated sales of around €12.7 billion and an operating profit (adjusted EBITDA) of about €2.165 billion.

About Resource Efficiency

The Resource Efficiency segment is led by Evonik Resource Efficiency GmbH and supplies high performance materials for environmentally friendly as well as energy-efficient systems to the automotive, paints & coatings, adhesives, construction, and many other industries. This segment employed about 9,000 employees, and generated sales of around €4.5 billion in 2016.

Disclaimer

In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.

SOURCE: Evonik

Contacts
Specialized Press Contact
Simone Herrwerth
Market Communication – Active Oxygens
+49 6181 59-13622
E-mail